Literature DB >> 19709676

Statistical methods for the analysis of relapse data in MS clinical trials.

Y C Wang1, L Meyerson, Y Q Tang, N Qian.   

Abstract

Patients with multiple sclerosis (MS) often experience unpredictable recurrent relapses with periods of remission. The modeling of MS relapse data is complicated because both within-subject serial dependence between relapses and between-patient heterogeneity may exist. We compare six statistical methods for assessing the treatment efficacy in reducing the frequency of relapses in MS clinical trials. All methods can be implemented in SAS, and are grouped into two classes, one based on Poisson-type regressions for count data and the other on Cox proportional hazards models for time to relapse. We apply these models to the data of a Tysabri (Natalizumab) MS trial and interpret the differences in results based on the underlying assumptions. Negative binomial regression is recommended for evaluating the overall treatment effect because of its simplicity and efficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19709676     DOI: 10.1016/j.jns.2009.07.017

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

1.  A parametric model fitting time to first event for overdispersed data: application to time to relapse in multiple sclerosis.

Authors:  Paola Siri; Eric Henninger; Maria Pia Sormani
Journal:  Lifetime Data Anal       Date:  2011-11-15       Impact factor: 1.588

2.  Estimating time-varying effects for overdispersed recurrent events data with treatment switching.

Authors:  Qingxia Chen; Donglin Zeng; Joseph G Ibrahim; Mouna Akacha; Heinz Schmidli
Journal:  Biometrika       Date:  2013       Impact factor: 2.445

3.  Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials.

Authors:  Leonard H Verhey; Alessio Signori; Douglas L Arnold; Amit Bar-Or; A Dessa Sadovnick; Ruth Ann Marrie; Brenda Banwell; Maria Pia Sormani
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

4.  Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials.

Authors:  Makiko N Mieno; Takuhiro Yamaguchi; Yasuo Ohashi
Journal:  BMC Med Res Methodol       Date:  2011-05-26       Impact factor: 4.615

5.  A systematic comparison of recurrent event models for application to composite endpoints.

Authors:  Ann-Kathrin Ozga; Meinhard Kieser; Geraldine Rauch
Journal:  BMC Med Res Methodol       Date:  2018-01-04       Impact factor: 4.615

6.  Population-Based Pharmacokinetic and Exposure-Efficacy Analyses of Peginterferon Beta-1a in Patients With Relapsing Multiple Sclerosis.

Authors:  Xiao Hu; Yaming Hang; Yue Cui; Jie Zhang; Shifang Liu; Ali Seddighzadeh; Aaron Deykin; Ivan Nestorov
Journal:  J Clin Pharmacol       Date:  2017-04-10       Impact factor: 3.126

7.  Semi-parametric analysis of overdispersed count and metric data with varying follow-up times: Asymptotic theory and small sample approximations.

Authors:  Frank Konietschke; Tim Friede; Markus Pauly
Journal:  Biom J       Date:  2018-12-05       Impact factor: 2.207

8.  A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.

Authors:  Marios C Pantzaris; George N Loukaides; Evangelia E Ntzani; Ioannis S Patrikios
Journal:  BMJ Open       Date:  2013-04-17       Impact factor: 2.692

9.  Developing a clinical-environmental-genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome.

Authors:  Valery Fuh-Ngwa; Yuan Zhou; Jac C Charlesworth; Anne-Louise Ponsonby; Steve Simpson-Yap; Jeannette Lechner-Scott; Bruce V Taylor
Journal:  Brain Commun       Date:  2021-12-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.